Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring health care information both rapidly and directly to the consumer or healthcare provider. CEO, Ray Akers, features some of company's proprietary testing products, including diabetes complication and lung cancer diagnostics. Growth is derived from global strategic partnerships and distributors like Cardinal Health, Thermo Fisher and Medline. AKER is now trading for more than cash and Akers believes is it a great value and time for investors to look at the company due to rapid sales trends and product commercialization. Jill Malandrino reports from the NASDAQ Market Site in New York.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.